Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cancer immunotherapy in patients with brain metastases

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exercise and cancer: from "healthy" to "therapeutic"?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. PD-L1-specific T cells

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Broadening the repertoire of melanoma-associated T-cell epitopes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Peripheral memory T cells specific for Arginase-1

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Real-world evidence to guide healthcare policies in oncology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. undersøges !!

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The exclusion of "real-world" patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a "real-world" setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy : CII
Vol/bind67
Udgave nummer5
Sider (fra-til)703-711
Antal sider9
ISSN0340-7004
DOI
StatusUdgivet - maj 2018

ID: 54806559